Interferon Patents (Class 424/85.4)
-
Publication number: 20140220132Abstract: The current invention pertains to pharmaceutical formulation including at least one jasmonate compound of the jasmonate family of compounds combined with a carrier, such as inclusion compounds, particularly those able to form nano or micro encapsulation systems. The invention generally refers to inclusion complexes which includes jasmonate compounds.Type: ApplicationFiled: February 27, 2012Publication date: August 7, 2014Inventor: José E. Fehr Pereira Lopes
-
Publication number: 20140212381Abstract: Cyclosporin derivatives, methods of manufacturing the cyclosporin derivatives and methods for treating subjects infected with certain viruses, including hepatitis virus or HIV by administering the cyclosporin derivatives are described.Type: ApplicationFiled: October 21, 2013Publication date: July 31, 2014Applicant: Scynexis, Inc.Inventors: Keqiang Li, Michael Robert Peel
-
Publication number: 20140212384Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.Type: ApplicationFiled: August 17, 2012Publication date: July 31, 2014Inventors: Jill Walker, Christian Voitenleitner
-
Publication number: 20140212382Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2?-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.Type: ApplicationFiled: May 16, 2012Publication date: July 31, 2014Applicants: EMORY UNIVERSITY, RFS PHARMA, LLCInventors: Raymond F. Schinazi, Jong Hyun Cho, Longhu Zhou, Hongwang Zhang, Ugo Pradere, Steven J. Coats
-
Publication number: 20140205566Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: wherein R1, R2 and R3 are as defined herein.Type: ApplicationFiled: November 21, 2013Publication date: July 24, 2014Applicant: NOVARTIS AGInventors: Lv LIAO, Fumiaki YOKOKAWA, Gang WANG
-
Publication number: 20140205567Abstract: The present invention discloses a class of novel macro-heterocyclic compounds represented by the formula Ia or Ib, and their intermediates, preparation methods and the uses. The macro-heterocyclic compounds of the present invention have good inhibitory activities against hepatitis C virus (HCV), and can be used to treat HCV infection effectively by its excellent inhibition against HCV, low toxicity and side effects.Type: ApplicationFiled: June 14, 2012Publication date: July 24, 2014Applicant: AB Pharma Ltd.Inventor: Zheng-yun James Zhan
-
Publication number: 20140205564Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Inventors: Jeffrey Lee Romine, Denis R. St. Laurent, Makonen Belema, Lawrence B. Snyder, Lawrence G. Hamann, John F. Kadow, Jayne Kapur, Andrew C. Good, Omar D. Lopez, Rico Lavoie, John A. Bender
-
Publication number: 20140205568Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.Type: ApplicationFiled: March 7, 2014Publication date: July 24, 2014Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Hugues De The, Valerie Lallemand-Breitenbach
-
Patent number: 8784797Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.Type: GrantFiled: December 15, 2009Date of Patent: July 22, 2014Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of BrirutInventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
-
Publication number: 20140199263Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: August 16, 2012Publication date: July 17, 2014Inventors: Casey Cameron McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Zhong Lai, Qun Dang, Nicolas Zorn
-
Publication number: 20140199262Abstract: The present invention provides a method for manufacturing a virus-free protein drug, comprising (a) a filtration step of filtering a virus-containing protein solution through a small-pore size virus removal membrane to obtain a virus-free protein solution, the filtration step (a) comprising (q) a low-pressure filtration step of filtering the solution through the small-pore size virus removal membrane at a filtration pressure of 0.30 kgf/cm2 or lower to obtain the virus-free protein solution, wherein the solution prior to filtration in the low-pressure filtration step (q) has a pH (X) and a salt ionic strength (Y (mM)) that satisfy the following equations 1 and 5: 0?Y?150X?590 (Equation 1) and 3.5?X?8.0 (Equation 5) or the following equations 4 and 5: Y=0 (Equation 4) and 3.5?X?8.0 (Equation 5).Type: ApplicationFiled: June 22, 2012Publication date: July 17, 2014Applicant: ASAHI KASEI MEDICAL CO., LTD.Inventors: Tomoko Hongo, Hirohisa Hayashida
-
Publication number: 20140199259Abstract: The present invention relates to a liquid formulation comprising an active substance and protamine, wherein the liquid formulation differs from a suspension.Type: ApplicationFiled: May 28, 2013Publication date: July 17, 2014Inventors: Heinrich Franz MATOUS, Andreas ZIMMER
-
Publication number: 20140199261Abstract: Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.Type: ApplicationFiled: July 25, 2013Publication date: July 17, 2014Applicants: Universite de Strasbourg, NormOxys, Inc.Inventors: Yves Claude Nicolau, Jean-Marie Lehn, Claudine Kieda
-
Publication number: 20140200188Abstract: Provided are methods for treating Orthomyxoviridue virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.Type: ApplicationFiled: January 24, 2014Publication date: July 17, 2014Inventors: Michael O'Neil Hanrahan Clarke, Choung U. Kim, Willard Lew
-
Publication number: 20140193360Abstract: The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same.Type: ApplicationFiled: November 21, 2011Publication date: July 10, 2014Applicant: Innotherapy Inc.Inventors: Haeshin Lee, Moon Sue Lee, Ji Hyun Ryu
-
Publication number: 20140193362Abstract: Disclosed are immunotherapeutic compositions and methods for preventing and/or treating hepatitis delta virus (HDV) infection, including yeast-based HDV immunotherapeutic compositions and methods of use of such compositions to prevent and/or treat HDV infection and symptoms and sequela thereof.Type: ApplicationFiled: June 14, 2012Publication date: July 10, 2014Applicant: GLOBEIMMUNE, INC.Inventors: Thomas H. King, David Apellan
-
Publication number: 20140193363Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 15, 2014Publication date: July 10, 2014Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
-
Patent number: 8771666Abstract: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-?). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-? and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-?.Type: GrantFiled: December 13, 2012Date of Patent: July 8, 2014Assignee: Medical Diagnostics Laboratories, LLCInventors: Grant Gallagher, Joyce Gallagher, Sshekar Srinivas, Jihong Dai, Nicholas Megjugorac, Grant E. Gallagher
-
Patent number: 8771665Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R1A, R1B, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.Type: GrantFiled: December 16, 2011Date of Patent: July 8, 2014Assignee: Cocrystal Discovery, Inc.Inventors: Sam S K Lee, Wang Shen, Xiaoling Zheng, Irina C. Jacobson
-
Publication number: 20140186299Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
-
Publication number: 20140178336Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 14, 2013Publication date: June 26, 2014Inventor: Gilead Sciences, Inc.
-
Publication number: 20140178337Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: George D. Hartman, Osvaldo A. Flores
-
Publication number: 20140178294Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140170064Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.Type: ApplicationFiled: December 18, 2013Publication date: June 19, 2014Applicant: Genentech, Inc.Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
-
Patent number: 8753671Abstract: The present invention relates to a method for preparing by wet spinning a continuous filament based on hyaluronic acid in free acid form, notably soluble in water. The preparation method according to the invention comprises the following steps: a) preparing a spinnable aqueous solution of hyaluronic acid or of a hyaluronic acid salt, preferably a sodium hyaluronate solution; b) extruding said solution to an extrusion die; c) forming the filament by passing the extruded solution into a bath of acetic acid, concentrated to more than 80%, drawing and drying. The invention also relates to a filament based on hyaluronic acid in free acid form, said filament having swelling properties in water and physiological liquids and moreover being solubilizable in water under certain conditions.Type: GrantFiled: September 26, 2008Date of Patent: June 17, 2014Assignees: Universite Claude Bernard Lyon I, Centre National de la Recherche ScientifiqueInventors: Alain Domard, Laurent David, Florence Dupasquier
-
Publication number: 20140161769Abstract: The present invention features a method of treating or reducing the likelihood of an inflammatory autoimmune disorder (e.g., systemic lupus erythematosus (SLE)) or a kidney disorder (e.g., glomerulonephritis) in a subject by administering an inhibitor of calcium/calmodulin-dependent protein kinase type IV (CaMKIV). The invention additionally features methods of diagnosing a subject with SLE or a kidney disorder by determining the level or biological activity of a CaMKIV nucleic acid or polypeptide in a sample from a subject. Also included in the invention are methods for identifying compounds that inhibit CaMKIV for the treatment of an inflammatory autoimmune disorder (e.g., SLE) or a kidney disorder (e.g., glomerulonephritis).Type: ApplicationFiled: July 8, 2013Publication date: June 12, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: George C. Tsokos, Yuang-Taung Juang, Chun-Shin Hahn
-
Publication number: 20140161858Abstract: Thermoplastic elastomer compositions are described comprising multigraft copolymers. The multigraft copolymers can comprise a rubbery polymeric backbone and a plurality of glassy polymeric side chains, each attached at one of a plurality of branch points randomly spaced along the backbone. The copolymer materials have high tensile strength, high strain at break, and low residual strain after elongation. The compositions can be used as adhesives and in a wide variety of high tech, medical, and commodity applications.Type: ApplicationFiled: September 30, 2011Publication date: June 12, 2014Applicant: University of Tennessee Research FoundationInventors: Jimmy W Mays, Liane Weidisch, Samuel P Gido, Christina Weidisch
-
Publication number: 20140154208Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.Type: ApplicationFiled: November 27, 2013Publication date: June 5, 2014Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: Yat Sun Or, In Jong Kim, Jiang Long, Lijuan Jiang, Sheng Sean Liu, Guoqiang Wang
-
Publication number: 20140154210Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: ApplicationFiled: March 11, 2013Publication date: June 5, 2014Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Publication number: 20140154207Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).Type: ApplicationFiled: February 6, 2014Publication date: June 5, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Yufang Shi, Liying Zhang, Guangwen Ren
-
Publication number: 20140147509Abstract: A particle is disclosed. The particle comprising: (i) at least one inner core which comprises a solid matrix of nutrients for microorganism growth; (ii) an inner membrane being fabricated from a water-soluble polymer, the inner membrane surrounding the inner core and a population of dried microorganisms; and (iii) an outer porous membrane surrounding the inner membrane, the outer porous membrane being insoluble in water. Methods of generating same, propagating microorganisms within and uses of same are also disclosed.Type: ApplicationFiled: February 2, 2014Publication date: May 29, 2014Inventor: Ofir MENASHE
-
Publication number: 20140147503Abstract: The present invention relates to a pharmaceutical composition comprising deferasirox, a process for preparing such pharmaceutical composition, and its use in the treatment of chronic iron overload. The pharmaceutical composition comprises nanosized deferasirox having improved surface area and solubility. It also relates to a method for treatment of chronic iron overload which comprises administering a pharmaceutical composition comprising nanosized deferasirox.Type: ApplicationFiled: September 30, 2011Publication date: May 29, 2014Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Publication number: 20140147413Abstract: The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.Type: ApplicationFiled: February 28, 2012Publication date: May 29, 2014Inventors: Dong Feng Chen, Jianzhu Chen, Huihui Chen
-
Patent number: 8734777Abstract: Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.Type: GrantFiled: August 10, 2011Date of Patent: May 27, 2014Assignee: Roche Palo Alto LLCInventors: Jim Li, Francisco Xavier Talamas
-
Patent number: 8735171Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.Type: GrantFiled: January 13, 2011Date of Patent: May 27, 2014Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Hugues De The, Valerie Lallemand-Breitenbach
-
Publication number: 20140140951Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein is an isolated compound according to Formula Ia: or a pharmaceutically acceptable salt or solvate thereof.Type: ApplicationFiled: November 13, 2013Publication date: May 22, 2014Inventors: Adel M. MOUSSA, Benjamin Alexander MAYES, Cyril B. DOUSSON, David DUKHAN
-
Publication number: 20140140952Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein is an isolated compound according to Formula Ib: or a pharmaceutically acceptable salt or solvate thereof.Type: ApplicationFiled: November 13, 2013Publication date: May 22, 2014Inventors: Adel M. MOUSSA, Benjamin Alexander MAYES, Cyril B. DOUSSON, David DUKHAN
-
Publication number: 20140140924Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.Type: ApplicationFiled: November 14, 2013Publication date: May 22, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen, Zhengxing Qu, Chien-Hsing Chang
-
Patent number: 8729023Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.Type: GrantFiled: December 11, 2012Date of Patent: May 20, 2014Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of IllinoisInventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Publication number: 20140134130Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Inventors: Tao Wang, Zhiwei Yin, Paul Michael Scola
-
Publication number: 20140134132Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: September 26, 2013Publication date: May 15, 2014Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20140127301Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.Type: ApplicationFiled: November 19, 2013Publication date: May 8, 2014Applicants: Massachusetts Institute of Technology, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.Inventors: Frank Alexis, Matteo Iannacone, Jinjun Shi, Pamela Basto, Elliott Ashley Moseman, Ulrich von Andrian, Robert S. Langer, Omid C. Farokhzad, Elena Tonti
-
Publication number: 20140127157Abstract: Antiviral activity of Nilotinib against Hepatitis C virus.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Inventors: Erica Canino, Adam Feire, Christopher Jones, Paul W. Manley
-
Publication number: 20140127156Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: October 28, 2013Publication date: May 8, 2014Inventors: Li-Qiang Sun, Qian Zhao, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshim, Eric P. Gillis, Paul Michael Scola
-
Patent number: 8715637Abstract: A novel IFN-?/? independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-?1, IFN-?2, IFN-?3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-? proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-?R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-?R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection.Type: GrantFiled: October 5, 2010Date of Patent: May 6, 2014Assignee: Rutgers, The State University of New JerseyInventors: Sergei Kotenko, Grant F. Gallagher
-
Patent number: 8715638Abstract: The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19, R22, R23, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.Type: GrantFiled: August 19, 2009Date of Patent: May 6, 2014Assignees: Merck Sharp & Dohme Corp., Southern Research InstituteInventors: Cecil D. Kwong, F. George Njoroge, Subramaniam Ananthan, Jeremy Clark, Feng Geng, Hollis S. Kezar, III, Joseph A. Maddry, John J. Piwinski, Robert C. Reynolds, Abhijit Roychowdhury, John A. Secrist, III, Neng-Yang Shih
-
Publication number: 20140120059Abstract: Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 8, 10 and 12 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 85% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.Type: ApplicationFiled: May 18, 2012Publication date: May 1, 2014Applicant: TORAY INDUSTRIES, INC.Inventors: Akira Kurihara, Fumiyoshi Okano
-
Patent number: 8709996Abstract: The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight of 1 KDa or less, a peptide, a protein or a polysaccharide. The compositions of the invention provide enhance absorption of the drug compound.Type: GrantFiled: April 23, 2010Date of Patent: April 29, 2014Assignee: Archimedes Development LimitedInventors: Michael Leane, Alan Smith, Lisbeth Illum
-
Publication number: 20140112865Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: ApplicationFiled: November 22, 2013Publication date: April 24, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20140112886Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2?-methyl nucleotides linked according to Formula I: N1-L-N2??(I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N1, L and N2 are as described herein.Type: ApplicationFiled: October 18, 2013Publication date: April 24, 2014Inventors: Adel M. MOUSSA, Benjamin Alexander MAYES, Jeevanandam ARUMUGASAMY, Jingyang WANG